Zynerba Pharmaceuticals, Inc.
ZYNE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.06 | -0.06 | 0.09 |
| FCF Yield | -102.52% | -29.63% | -46.83% | -26.30% |
| EV / EBITDA | 0.80 | -1.27 | -0.58 | -1.85 |
| Quality | ||||
| ROIC | -75.24% | -51.85% | -84.84% | -43.12% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.90 | 0.80 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 30.81% | 19.77% | -19.49% | -6.92% |
| Safety | ||||
| Net Debt / EBITDA | 1.45 | 1.86 | 1.13 | 2.04 |
| Interest Coverage | 163.40 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |